The role of targeted therapy and biomarkers in breast cancer treatment

Clinical and Experimental Metastasis

Volumn 29, Issue 7, 2012, Pages 807-819

  Stopeck, Alison T ^a   Brown Glaberman, Ursa ^a   Wong, Hong Yuen ^b   Park, Ben Ho ^b   Barnato, Sara E ^c   Gradishar, William J ^c   Hudis, Clifford A ^d   Rugo, Hope S ^e  

^a UNIVERSITY OF ARIZONA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Biomarkers; Breast cancer; Chemotherapy; Her2; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERIBULIN; FLUOROURACIL; GEMCITABINE; LAPATINIB; NERATINIB; NIRAPARIB; OLAPARIB; PACLITAXEL; PERTUZUMAB; RUCAPARIB; TEMSIROLIMUS; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VELIPARIB;

ADVANCED CANCER; ANGIOGENESIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CONFERENCE PAPER; DIARRHEA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HISTOPATHOLOGY; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTOR VARIABLE; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84868191543     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9496-y     Document Type: Conference Paper

References (94)

1. Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
2. Marty MA et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274
3. Cobleigh MA et al (2005) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648
4. Robert N et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786-2792
5. Wardley AM et al (2010) Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 28:976-983
6. Chan A et al (2006) Vinorelbine plus trastuzumab combination as first-line therapy for HER2-positive metastatic breast cancer patients: An international phase II trial. Br J Cancer 95:788-793
7. Yardley DA (2009) Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 9:178-183
8. Ewer MS et al (2005) Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820-7826
9. de Azambuja E et al (2009) Cardiac toxicity with anti-HER2 therapies: What have we learned so far? Target Oncol 4:77-88
10. Geyer CE et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743
11. Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130
12. Blackwell KL, Burstein HJ, Sledge GW et al (2009) Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. In: San Antonio breast cancer symposium, San Antonio, TX. Abstract 61
13. Glaxo Smith Kline (2011) Lapatinib clinical trial update. London. http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-614837.htm. Accessed April 11, 2012
14. Baselga J et al (2010) First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer [abstract S3-3]. Cancer Res 70(suppl 24):82s
15. Scheuer W et al (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment of HER2-positive human xenograft tumor models. Cancer Res 69: 9330-9336
16. Gianni L et al (2010) Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Cancer Res 70 (Suppl. 2):S3-2
17. Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2:109-119
18. Burris HA et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2(HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405
19. Krop I et al (2010) A phase II study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib and chemotherapy. Ann Oncol 21(suppl 8):viii96-viii121
20. Perez EA (2010) Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: Preliminary results of a randomized, multicenter, open-label phase II study (TDM4450 g). Ann Oncol 21(suppl 8):viii2
21. A Study of Trastuzumab Emtansine (T-DM1) Plus pertuzumab/ pertuzumab placebo versus trastuzumab [herceptin] plus a taxane in patients with metastatic breast cancer (MARIANNE) (2012) http://clinicaltrials.gov/ct2/show/NCT01120184. Accessed April 11, 2012
22. An Open-Label Study of Trastuzumab Emtansine (T-DM1) Vs Capecitabine ? Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA) (2012). http://clinicaltrials.gov/ct2/show/NCT00829166. Accessed April 11, 2012
23. Roche Media Release (2012) http://www.roche.com/media/ media-releases/med-cor-2012-03-30.htm. Accessed May 9, 2012
24. Burnstein HJ et al (2010) Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307
25. Martin M, Bonneterre J, Geyer, Jr CE (2011) A phase 2, randomized, open-label, study of neratinib (HKI-272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2? locally advanced or metastatic breast cancer. In: San Antonio breast cancer symposium, San Antonio, TX. Abstract S5-7
26. Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer (NEFERTT) (2012) http:// clinicaltrials.gov/ct2/show/NCT00915018. Accessed April 11, 2012
27. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
28. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
29. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145
30. Riely GJ, Marks J, Pao W (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6:201-205
31. Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402
32. Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127
33. Jensen JD, Knoop A, Laenkholm AV et al (2011) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol [Epub ahead of print]
34. Dressman D, Yan H, Traverso G et al (2003) Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 100:8817-8822
35. Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985-990
36. Higgins MJ, Jelovac D, Barnathan E et al (2011) Improving detection methods for PIK3CA mutations in breast cancer using peripheral blood from patients with metastastic breast cancer (MBC). J Clin Oncol 29(suppl):Abstract 10512
37. Dawood S, Lei X, Litton JK et al (2012) Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer [Epub ahead of print]
38. Hudis CA, Gianni L (2011) Triple-negative breast cancer: An unmet medical need. Oncologist 16(suppl 1):1-11
39. Perou CM (2010) Molecular stratification of triple-negative breast cancers. Oncologist 15(suppl 5):39-48
40. Metzger-Filho O, Tutt A, de Azambuja E et al (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol [Epub ahead of print]
41. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer. J Clin Oncol 26:1275-1281
42. Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168-1176
43. Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506
44. Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28: 375-379
45. Silver DP, Richardson AL, Eklund AC et al (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153
46. Gelmon KA, Tischkowitz M, Mackay H et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852-861
47. O'Shaughnessy J, Osborne C, Pippen JE (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205-214
48. O'Shaughnessy J, Schwartzberg LS, Danso MA et al (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (G/C) in metastatic triplenegative breast cancer (TNBC). J Clin Oncol 29(suppl):Abstract 1007
49. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH (2012) Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 18:1655-1662
50. Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376:235-244
51. Foekens JA, Peters HA, Grebenchtchikov N et al (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407-5414
52. Linderholm BK, Hellborg H, Johansson U et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20:1639-1646
53. Hu Z, Fan C, Livasy C et al (2009) A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 7:9
54. Brufsky A, Valero V, Tiangco B et al (2012) Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: Subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat [Epub ahead of print]
55. von Minckwitz G, Eidtmann H, Rezai M et al (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299-309
56. Greenberg S, Rugo HS (2010) Triple-negative breast cancer: Role of antiangiogenic agents. Cancer J 16:33-38
57. Viale G, Rotmensz N, Maisonneuve P et al (2009) Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: Prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116:317-328
58. Carey L, Winer E, Viale G et al (2010) Triple-negative breast cancer: Disease entity or title of convenience? Nat Rev Clin Oncol 7:683-692
59. Moulder S, Moroney J, Helgason T et al (2011) Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: Biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol 29:e572-e575
60. Oliver PG, Lobuglio AF, Zhou T et al (2011) Effect of anti-DR5 and chemotherapy on basal-like breast cancer. Breast Cancer Res Treat [Epub ahead of print]
61. Reedijk M (2012) Notch signaling and breast cancer. Adv Exp Med Biol 727:241-257
62. Sharma A, Paranjape AN, Rangarajan A, Dighe RR (2012) A monoclonal antibody against human Notch1 ligand-binding domain depletes subpopulation of putative breast cancer stemlike cells. Mol Cancer Ther 11:77-86
63. Doane AS, Danso M, Lal P (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25:3994-4008
64. Campbell MJ, Tonlaar NY, Garwood ER (2011) Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 28:703-711
65. Ruffell B, Au A, Rugo HS et al (2012) Leukocyte composition of human breast cancer. Proc Natl Acad Sci USA 109:2796-2801
66. Denardo DG, Brennan DJ, Rexhepaj E et al (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1:54-67
67. Recent Trends in Mortality Rates for Four Major Cancers, by Sex and Race/Ethnicity, United States, 1990-1998. http://www.cdc. gov/mmwr/preview/ mmwrhtml/mm5103a1.htm. Accessed May 9, 2012
68. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823
69. Sparano JA, Vrdoljak E, Rixe O et al (2010) Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28:3256-3263
70. Broglio KR, Berry DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649
71. Cortes J, O'Shaughnessy J, Loesch D (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomized study. Lancet 377:914-923
72. Alitalo A, Detmra M (2011) Interactions of tumor cells and lymphatic vessels in cancer progression.Oncogene [Epub ahead of print]
73. Mancuso P, Bertolini F (2010) Circulating endothelial cells as biomarkers in clinical oncology. Microvasc Res 79:224-228
74. Weis SM, Cheresh DA (2011) Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med 17:1359-1370
75. Roskoski R (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62: 179-213
76. Kaipainen A, Korhonen J, Mustonen T et al (1995) Expression of fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92:3566-3570
77. Laakkonen P, Waltari M, Holpainen T et al (2002) Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 67:539-599
78. Thiele W, Sleeman JP (2006) Tumor-induced lymphangiogenesis: A target for cancer therapy? J Bioterchnol 124:224-241
79. Brown-Glaberman U, Specht J, Iannone M et al (2011) Circulating endothelial cells and plasma VCAM in patients receiving antiangiogenic therapy for locally advanced breast cancer (poster presentation). In: 4th International Symposium on Cancer Metastasis and the lymphovascular system: Basis for rational therapy, New York, NY
80. Giovannini M, Aldrighetti D, Zucchinelli P (2010) Antiangiogenic strategies in breast cancer management. Crit Rev Oncol Hematol 76:13-35
81. A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer (2012) http://clinicaltrials.gov/ct2/show/study/ NCT00511459?s how-locs=Y#locn. Accessed April 10, 2012
82. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast cancer. N Engl J Med 324:1-8
83. Hormbrey E, Gillespie P, Turner K et al (2002) A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: Is the current literature meaningful? Clin Exp Metastasis 19:651-663
84. Niers TM, Richel DJ, Meijers JC, Schlingemann RO (2011) Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One 6:e19873. [Epub ahead of print]
85. A Stopeck, J Unger, L Rimsza et al (2010) Phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab (R-CHOP) plus bevacizumab for advanced stage diffuse large B-cell (DLBCL) NHL: Southwest oncology group study S0515. In: American Society of hematology annual meeting. Blood 116:Abstract 591
86. Byrne GJ, Ghellal A, Iddon J et al (2000) Serum vascualr adhesion moleculte-1: Role as a surrogate marker of angiogenesis. J Nat Cancer Inst 92:1329-1336
87. van der Veldt AAM, Vroling L, de Haas RR et al (2011) Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. Int J Cancer [Epub ahead of print]
88. Baar J, Silverman P, Lyons J et al (2009) A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: Impact on angiogenic biomarkers. Clin Cancer Res 15:3583-3590
89. Mancuso P, Burlini A, Pruneri G et al (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658-3661
90. Beerepoot LV, Mehra N, Vermatt JSP et al (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15:139-145
91. Calleri A, Bono A, Bagnardi V et al (2009) Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15:7652-7657
92. Mancuso P, Colleoni M, Calleri A et al (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108: 452-459
93. Stopeck AT, Unger JM, Rimsza LM et al (2009) A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 50:728-735
94. Jain RK, Duda DG, Willett CG (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338